Benzinga··Globe NewswireGSK Acquires 35Pharma for $950M to Advance Pulmonary Hypertension Treatment
GSK acquires 35Pharma for $950M to gain HS235, a clinical-stage pulmonary hypertension drug with improved safety profiles versus existing treatments.
GSKacquisitionclinical development